HR positive HER2 negative advanced breast carcinoma
Conditions
Interventions
Experimental group:Vinorelbine combined with entinostat
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 years; 2. Patients with advanced breast carcinoma confirmed by histopathological and / or cytological examination; 3. HR positive HER2-negative breast carcinoma with confirmed primary and / or metastatic lesions; 4. There must be at least one evaluable tumor lesion (according to RECIST1.1); 5. Patients who have previously received 2-4 lines of treatment must include endocrine therapy combined with CDK4/6 inhibitors, chemotherapy containing paclitaxel as the first-line treatment, and ADC drugs as the first-line treatment, if applicable. 6. Comprehensive clinical data are available for important research indicators. 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; 8. Life expectancy > 6 months;
Exclusion criteria
Exclusion criteria: 1. Male with breast carcinoma; 2. Have other malignant neoplasms; 3. Patients with incomplete clinical case characteristics; 4. Previous or current metastatic disease of the central nervous system or leptomeninges; 5. Women during pregnancy and breastfeeding; 6. Other reasons have led the researcher to believe that the participant is not suitable for this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, OS;Objective Response Rate, ORR;Disease Control Rate, DCR;Safety; | — |
Primary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS; | — |
Countries
China
Contacts
Public ContactChen Wang
Tianjin Medical University Cancer Institute and Hospital
Outcome results
None listed